New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years : vimarsana.com

New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with...

Related Keywords

Canada , Washington , United States , Japan , University Of Washington , Spring House , British Columbia , Horsham , Saskatchewan , Seattle , Donvitot Creakyjoints , Terence Rooney , Philip Mease , Bridget Kimmel , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Swedish Medical Center Providence , National Psoriasis Foundation , None Of The Janssen Pharmaceutical Companies , Form Health Survey Physical Component Summary , European Congress , Joseph Health , Drug Administration , Health Assessment Questionnaire , Guselkumab Provides Sustained Improvements In Health , Exchange Commission , Companies Of Johnson , Group For Research , Johnson , Swedish Medical , Efficacy Across Joint , Psoriatic Arthritis , Disease Activity Index , Radiographic Progression , Work Productivity , Short Form , Vitality Scale , Functional Assessment , Chronic Illness Therapy , Vice President , Maternal Fetal Disease Area , Janssen Research , Disease Activity , Psoriasis Area Severity Index , Global Assessment , Psoriatic Arthritis Disease Activity Score , Disability Index , Euroqol Visual Analog Scale , Item Short Form Health Survey , Physical Component Summary , Mental Component Summary , Prescribing Information , Medication Guidefor , Pharmaceutical Companies , Infectious Diseases , Private Securities Litigation Reform Act , Annual Report , Note Regarding Forward Looking , Quarterly Reports , Baseline Patient , Provides Sustained Improvements , Health Related Quality , Patients With Active Psoriatic Arthritis Through , Associated With Fatigue , Its Improvement , Principal Component Analysis , Patients With Active Psoriatic Arthritis , Guselkumab Phase , Pain Response , Psoriatic Arthritis Receiving Treatment , Daily Activity , Accessed May , Provides Continued Improvement , Key Domains , Psoriatic Arthritis Through , Minimal Disease Activity Achievement , Patients With Psoriatic Arthritis Receiving , Data From The Phase , Maintains Resolution , Results Through , Axial Related Endpoints , Patients With Active Psa , Placebo Controlled Study Through , Radiographic Progression With , Selective Inhibitor , Placebo Controlled Study , Active Psoriatic , Arthritis Res Ther , Clinical Response Predict Low Rates , Active Psoriatic Arthritis , Pooled Results From , Clinical Trials Through , Safety Analyses , Long Term Results , Randomized Clinical Trials , Patients With Psoriatic Disease Utilizing , Results Through Week , Patients With Psoriasis , Oncol Clin North , Warm Autoimmune Hemolytic Anemia , Known Clinically Profiled , Painful Arthritis Symptom You Should Know , Sausage Finger Swelling You Should Know , Psoriatic Arthritis According , Different Definitions , Comparing Minimal Disease Activity , Arthritis Care Res , Study Evaluating , Guselkumab Administered Subcutaneously , Tumor Necrosis Factor , Alpha Agent , Participants With Active Psoriatic , Participants With Active Psoriatic Arthritis , Inadequate Response , Anti Tumor Necrosis Factor Alpha , Rambam Maimonides Med , About Psoriatic , Rheumatic Diseases , Immune Based Therapies , Janssen Pharmaceutical Companies Of Johnson Amp , Medical Pharmaceuticals , Health Care Amp Hospitals , Pharmaceuticals , Clinical Trials Amp Medical Discoveries ,